Related Experiment Video
Updated: Jul 20, 2026
07:26
Conducting Maximal and Submaximal Endurance Exercise Testing to Measure Physiological and Biological Responses to Acute Exercise in Humans
Published on: October 17, 2018
Exercise testing with concurrent beta-blocker usage: is it useful? What do we learn?
1Division of Cardiology, University of Colorado, Health Sciences Center, Denver, CO 80262, USA. gene.wolfel@uchsc.edu
Current Heart Failure Reports
|August 25, 2006
Summary
Cardiopulmonary exercise testing (CPET) provides prognostic insights for heart failure (HF). Beta-blocker therapy impacts CPET interpretation, necessitating updated risk stratification tools for improved patient survival.
Area of Science:
- Cardiology
- Exercise Physiology
Background:
- Cardiopulmonary exercise testing (CPET) assesses heart failure (HF) severity, with peak oxygen consumption (VO2) and ventilatory parameters historically used as prognostic indicators.
- Traditional CPET interpretation predates the widespread use of beta-adrenergic blockade as a primary HF therapy.
Purpose of the Study:
- To evaluate the prognostic value of CPET in patients with chronic heart failure receiving beta-blocker therapy.
- To determine if existing CPET thresholds for risk stratification remain valid in the era of beta-blockade.
Main Methods:
- Review of retrospective and prospective studies examining CPET in patients with chronic HF on beta-blocker therapy.
- Analysis of the impact of beta-blockade on the relationship between CPET parameters (peak VO2, ventilatory efficiency) and cardiovascular outcomes.
Main Results:
- Beta-blocker therapy is associated with improved cardiovascular outcomes in patients with chronic HF.
- Peak VO2 retains prognostic value in beta-blocked patients, but risk thresholds may need adjustment.
- Ventilatory parameters may offer additive prognostic information, potentially superior to peak VO2 in some cases.
Conclusions:
- CPET remains a valuable tool for prognostication in HF, even with beta-blocker use.
- A comprehensive survival score incorporating beta-blockade status and CPET performance is needed for accurate risk stratification.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:26Exercise Stress Test
Introduction
Exercise stress testing, commonly known as a treadmill test, is a noninvasive procedure used to evaluate cardiovascular function and diagnose heart conditions.
Definition
An exercise stress test measures the heart's response to exertion using a treadmill or stationary bicycle. Chest electrodes record the heart's electrical activity through an ECG, and blood pressure is monitored regularly.
Purposes
Exercise stress testing, commonly known as a treadmill test, is a noninvasive procedure used to evaluate cardiovascular function and diagnose heart conditions.
Definition
An exercise stress test measures the heart's response to exertion using a treadmill or stationary bicycle. Chest electrodes record the heart's electrical activity through an ECG, and blood pressure is monitored regularly.
Purposes
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...